(Q38459836)

3 September 2017

1 reference

title

Epigenetic therapy for solid tumors: from bench science to clinical trials (English)

1 reference

3 September 2017

5

Stephen B Baylin

1 reference

3 September 2017

Yen-Yi Juo

1

1 reference

3 September 2017

Xue-Jun Gong

2

1 reference

3 September 2017

Ankita Mishra

3

1 reference

3 September 2017

Xiao Cui

4

1 reference

3 September 2017

Nilofer S Azad

6

1 reference

3 September 2017

Nita Ahuja

7

1 reference

3 September 2017

publication date

1 January 2015

1 reference

3 September 2017

1 reference

3 September 2017

volume

7

1 reference

3 September 2017

issue

2

1 reference

3 September 2017

page(s)

215-235

1 reference

DNA methylation and epigenotypes

3 September 2017

cites work

1 reference

Interpreting the language of histone and DNA modifications

21 January 2018

1 reference

Histone methylation in transcriptional control

21 January 2018

1 reference

Most mammalian mRNAs are conserved targets of microRNAs

21 January 2018

1 reference

The future of epigenetic therapy in solid tumours--lessons from the past.

21 January 2018

1 reference

Gene silencing in cancer in association with promoter hypermethylation

21 January 2018

1 reference

Hypomethylation distinguishes genes of some human cancers from their normal counterparts

21 January 2018

1 reference

Global histone modification patterns predict risk of prostate cancer recurrence

21 January 2018

1 reference

The epigenetic progenitor origin of human cancer

21 January 2018

1 reference

Epigenetic alteration and microRNA dysregulation in cancer

21 January 2018

1 reference

DNMT1 and DNMT3b cooperate to silence genes in human cancer cells

21 January 2018

1 reference

Cancer epigenomics: DNA methylomes and histone-modification maps

21 January 2018

1 reference

Cellular differentiation, cytidine analogs and DNA methylation

21 January 2018

1 reference

Harnessing the potential of epigenetic therapy to target solid tumors.

21 January 2018

1 reference

Epigenetics in human disease and prospects for epigenetic therapy

21 January 2018

1 reference

Epigenetic targeting in pancreatic cancer

21 January 2018

1 reference

Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy

21 January 2018

1 reference

Targeting the epigenome for treatment of cancer.

21 January 2018

1 reference

Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells

21 January 2018

1 reference

Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer

21 January 2018

1 reference

Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers.

21 January 2018

1 reference

5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.

21 January 2018

1 reference

Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.

21 January 2018

1 reference

Cancer cells acquire resistance to anticancer drugs: an update

21 January 2018

1 reference

Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies

21 January 2018

1 reference

Inhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance

21 January 2018

1 reference

The novel HDAC inhibitor NDACI054 sensitizes human cancer cells to radiotherapy

21 January 2018

1 reference

Combination of AT-101/cisplatin overcomes chemoresistance by inducing apoptosis and modulating epigenetics in human ovarian cancer cells.

21 January 2018

1 reference

Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy

21 January 2018

1 reference

Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection.

21 January 2018

1 reference

FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension

21 January 2018

1 reference

DNA methyltransferase inhibitors in myelodysplastic syndrome

21 January 2018

1 reference

Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.

21 January 2018

1 reference

Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors

21 January 2018

1 reference

Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study

21 January 2018

1 reference

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction.

21 January 2018

1 reference

As we bring demethylating drugs to the clinic, we better know the DICE being cast

21 January 2018

1 reference

Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines.

21 January 2018

1 reference

Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides

21 January 2018

1 reference

S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth

21 January 2018

1 reference

Immunomodulatory activity of SGI-110, a 5-aza-2'-deoxycytidine-containing demethylating dinucleotide.

21 January 2018

1 reference

SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome

21 January 2018

1 reference

Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression

21 January 2018

1 reference

A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.

21 January 2018

1 reference

A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer

21 January 2018

1 reference

Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix

21 January 2018

1 reference

Cellular memory and the histone code

21 January 2018

1 reference

Histone deacetylases (HDACs): characterization of the classical HDAC family

21 January 2018

1 reference

Complicated tails: histone modifications and the DNA damage response

21 January 2018

1 reference

The activities of eukaryotic replication origins in chromatin

21 January 2018

1 reference

Post-translational modification of p53 in tumorigenesis

21 January 2018

1 reference

Regulation of activity of the transcription factor GATA-1 by acetylation

21 January 2018

1 reference

Regulation of E2F1 activity by acetylation

21 January 2018

1 reference

Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation

21 January 2018

1 reference

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

Mechanisms of suberoylanilide hydroxamic acid inhibition of mammary cell growth

21 January 2018

1 reference

Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites

21 January 2018

1 reference

Promises and challenges of anticancer drugs that target the epigenome

21 January 2018

1 reference

HDAC inhibitors: roles of DNA damage and repair

21 January 2018

1 reference

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

21 January 2018

1 reference

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

21 January 2018

1 reference

Current trends in the development of histone deacetylase inhibitors: a review of recent patent applications

21 January 2018

1 reference

Discovery and development of SAHA as an anticancer agent

21 January 2018

1 reference

Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer

21 January 2018

1 reference

A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study

21 January 2018

1 reference

Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma

21 January 2018

1 reference

A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer

21 January 2018

1 reference

Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study

21 January 2018

1 reference

Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study

21 January 2018

1 reference

Clinical and molecular responses in lung cancer patients receiving Romidepsin

21 January 2018

1 reference

Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304).

21 January 2018

1 reference

A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03.

21 January 2018

1 reference

Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine-refractory thyroid carcinoma

21 January 2018

1 reference

Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)

21 January 2018

1 reference

Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer

21 January 2018

1 reference

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).

21 January 2018

1 reference

Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeuti

21 January 2018

1 reference

A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group

21 January 2018

1 reference

Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy

21 January 2018

1 reference

Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal a

21 January 2018

1 reference

Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas

21 January 2018

1 reference

A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium

21 January 2018

1 reference

Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors

21 January 2018

1 reference

Gossypol and an HMT G9a inhibitor act in synergy to induce cell death in pancreatic cancer cells.

21 January 2018

1 reference

Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression

21 January 2018

1 reference

Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications

21 January 2018

1 reference

Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures

21 January 2018

1 reference

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

21 January 2018

1 reference

Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model

21 January 2018

1 reference

Epigenetic codes for heterochromatin formation and silencing: rounding up the usual suspects

21 January 2018

1 reference

A histone H3 methyltransferase controls DNA methylation in Neurospora crassa

21 January 2018

1 reference

Epigenetic interplay between histone modifications and DNA methylation in gene silencing

21 January 2018

1 reference

A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine.

21 January 2018

1 reference

Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes

21 January 2018

1 reference

ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor

21 January 2018

1 reference

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

21 January 2018

1 reference

Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance.

21 January 2018

1 reference

Epigenetic targeting of ovarian cancer stem cells

21 January 2018

1 reference

Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance.

21 January 2018

1 reference

Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2'-deoxycytidine on ovarian cancer

21 January 2018

1 reference

Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer

21 January 2018

1 reference

Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors

21 January 2018

1 reference

Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies

21 January 2018

1 reference

Epigenetic resensitization to platinum in ovarian cancer

21 January 2018

1 reference

A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer.

21 January 2018

1 reference

Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer

21 January 2018

1 reference

Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo

21 January 2018

1 reference

Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study

21 January 2018

1 reference

A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer

21 January 2018

1 reference

Differential DNA methylation alterations in radiation-sensitive and -resistant cells

21 January 2018

1 reference

Epigenetic interventions increase the radiation sensitivity of cancer cells

21 January 2018

1 reference

Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors

21 January 2018

1 reference

Histone deacetylase inhibitor NVP-LAQ824 sensitizes human nonsmall cell lung cancer to the cytotoxic effects of ionizing radiation

21 January 2018

1 reference

Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid/rhabdoid tumor cells.

21 January 2018

1 reference

Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic

21 January 2018

1 reference

Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma.

21 January 2018

1 reference

Cancer testis antigens in human melanoma stem cells: expression, distribution, and methylation status

21 January 2018

1 reference

Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells

21 January 2018

1 reference

Regulation of high molecular weight-melanoma associated antigen (HMW-MAA) gene expression by promoter DNA methylation in human melanoma cells

21 January 2018

1 reference

Methylation of the promoter of human leukocyte antigen class I in human esophageal squamous cell carcinoma and its histopathological characteristics.

21 January 2018

1 reference

Hypermethylation of HLA class I gene is associated with HLA class I down-regulation in human gastric cancer

21 January 2018

1 reference

Down-regulation of HLA class I antigens in prostate cancer tissues and up-regulation by histone deacetylase inhibition

21 January 2018

1 reference

Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid

21 January 2018

1 reference

Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B.

21 January 2018

1 reference

Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies

21 January 2018

1 reference

Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer

21 January 2018

1 reference

The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee

21 January 2018

1 reference

Alternate endpoints for screening phase II studies.

21 January 2018

1 reference

Considerations for the use of imaging tools for phase II treatment trials in oncology

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/EPI.14.73

1 reference

3 September 2017

1 reference